Falsely prolonged activated partial thromboplastin time - a pre- and post-analytical issue
- PMID: 30591818
- PMCID: PMC6294156
- DOI: 10.11613/BM.2019.011001
Falsely prolonged activated partial thromboplastin time - a pre- and post-analytical issue
Abstract
This case highlights two common pre-analytical problems identified in routine coagulation testing of activated partial thromboplastin time (aPTT), which were overlooked because of a concurrent flag code indicating no coagulation and the result was replaced by asterisks. It concerns a boy with gastrointestinal bleeding and prolonged aPTT > 300 seconds, which raised the suspicion of haemophilia. When all other coagulation parameters (including specific coagulation factors VIII and IX) turned out to be normal, aPTT was re-measured using another analysis principle, which revealed a normal aPTT. The primary aPTT result turned out to be aborted due to concurrent haemolysis and lipaemia, but was erroneously interpreted as prolonged coagulation. The lesson is awareness of the possibility of numerous flag codes on the same sample overruling each other, and awareness on the responsibility in the post-analytical phase that must be carried by increased educational focus and by the manufacturers.
Keywords: activated partial thromboplastin time; haemolysis; lipemia; post-analytical errors; pre-analytical errors.
Conflict of interest statement
Potential conflict of interest: None declared.
Figures
Similar articles
-
Artifactual prolongation of the activated partial thromboplastin time mimicking a coagulopathy. A lesson relearned.Am J Clin Pathol. 1993 Aug;100(2):108-10. doi: 10.1093/ajcp/100.2.108. Am J Clin Pathol. 1993. PMID: 8356940
-
The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal.Int J Lab Hematol. 2011 Apr;33(2):212-8. doi: 10.1111/j.1751-553X.2010.01266.x. Epub 2010 Sep 29. Int J Lab Hematol. 2011. PMID: 20880301
-
How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors.Semin Thromb Hemost. 2019 Feb;45(1):22-35. doi: 10.1055/s-0038-1677018. Epub 2019 Jan 10. Semin Thromb Hemost. 2019. PMID: 30630206
-
Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant.Clin Appl Thromb Hemost. 2015 Mar;21(2):149-54. doi: 10.1177/1076029614541516. Epub 2014 Jul 2. Clin Appl Thromb Hemost. 2015. PMID: 24989713 Review.
-
Implications of deranged activated partial thromboplastin time for anaesthesia and surgery.Anaesthesia. 2018 Dec;73(12):1557-1563. doi: 10.1111/anae.14344. Epub 2018 Oct 13. Anaesthesia. 2018. PMID: 30315725 Review.
Cited by
-
Activated Partial Thromboplastin Time and Anti-IIa Monitoring in Argatroban Anticoagulation in COVID-19 Patients on Venovenous Extracorporeal Membrane Oxygenation.Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251341315. doi: 10.1177/10760296251341315. Epub 2025 May 21. Clin Appl Thromb Hemost. 2025. PMID: 40396972 Free PMC article.
References
-
- Lippi G, Plebani M, Favaloro JE. Interference in Coagulation Testing: Focus on Spurious Hemolysis, Icterus, and Lipemia. Semin Thromb Hemost. 2013;39:258–66. - PubMed
-
- Clinical and Laboratory Standards Institute (CLSI). Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays. Approved Guideline - Fifth edition. CLSI document H21-A5. Wayne, USA: CLSI, 2008.